Dolutegravir Resistance in Malawi's National HIV Treatment Program.
Open Forum Infect Dis
; 9(5): ofac148, 2022 May.
Article
in En
| MEDLINE
| ID: mdl-35493118
ABSTRACT
Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020-September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 (30%) had dolutegravir HIVDR. Malawi urgently requires adequate HIVDR testing capacity.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Open Forum Infect Dis
Year:
2022
Document type:
Article
Affiliation country:
Malawi